Nomination committee appointed in respect of AGM 2017 in Alligator Bioscience AB (Publ)
According to the instruction for Nomination Committee in Alligator Bioscience AB (publ) adopted at the annual general meeting held on 20 Apr ...
Alligator Bioscience AB intends to list its shares on Nasdaq Stockholm
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER ...
Alligator Bioscience informs that dosing has started in a second clinical phase I study with the CD40 Agonistic Immuno-Oncology Antibody ADC-1013
– Janssen assumes responsibility for all future clinical studies Alligator started dosing in the first clinical phase I dose escalatio ...